BTG PLC (LON:BTG) Shareholders Are Liking The News That JP Morgan Cazenove Has Reiterated Their “Neutral” Rating on the Stock

April 23, 2018 - By Louis Casey

BTG plc (LON:BTG) Logo

BTG PLC (LON:BTG) Rating Reaffirmed

In analysts note revealed to investors and clients on Thursday, 21 September, JP Morgan Cazenove reiterated their “Neutral” rating on BTG PLC (LON:BTG) shares.

BTG plc (LON:BTG) Ratings Coverage

Among 5 analysts covering BTG PLC (LON:BTG), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. BTG PLC has GBX 900 highest and GBX 680 lowest target. GBX 763.75’s average target is 13.65% above currents GBX 672 stock price. BTG PLC had 17 analyst reports since October 31, 2017 according to SRatingsIntel. The firm has “Hold” rating given on Tuesday, November 14 by Peel Hunt. Peel Hunt maintained the stock with “Hold” rating in Tuesday, October 31 report. Peel Hunt maintained it with “Hold” rating and GBX 680 target in Monday, November 6 report. The company was maintained on Tuesday, November 7 by Deutsche Bank. The rating was maintained by Peel Hunt with “Hold” on Wednesday, April 4. On Thursday, February 1 the stock rating was maintained by Numis Securities with “Buy”. The firm has “Buy” rating given on Wednesday, January 24 by Numis Securities. The stock of BTG plc (LON:BTG) has “Neutral” rating given on Monday, January 15 by JP Morgan. The firm has “Neutral” rating by JP Morgan given on Friday, April 6. JP Morgan maintained BTG plc (LON:BTG) on Tuesday, November 7 with “Neutral” rating.

The stock increased 1.28% or GBX 8.5 during the last trading session, reaching GBX 672. About 593,389 shares traded. BTG plc (LON:BTG) has 0.00% since April 23, 2017 and is . It has underperformed by 11.55% the S&P500.

Analysts await BTG plc (LON:BTG) to report earnings on May, 10 before the open. They expect $0.06 earnings per share, up 200.00 % or $0.04 from last year’s $0.02 per share. BTG’s profit will be $231,875 for 2800.00 P/E if the $0.06 EPS becomes a reality. After $0.01 actual earnings per share reported by BTG plc for the previous quarter, Wall Street now forecasts 500.00 % EPS growth.

BTG plc acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, Asia, and internationally. The company has market cap of 2.60 billion GBP. It operates through three divisions: Interventional Medicine, Specialty Pharmaceuticals, and Licensing. It has a 35.37 P/E ratio. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.